Part:BBa_I718017:Experience

This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.

User Reviews

UNIQ382ce49a2a776105-partinfo-00000000-QINU UNIQ382ce49a2a776105-partinfo-00000001-QINU

igem2010 UT-Tokyo

Our Cre recombinase assay device (CRAD), BBa_K313009, is a part originally designed to report the functionality of the Cre recombinase. We used this part as the lox71 site and expected that the double-terminator between the lox66 site and the lox71 site will be excised irreversibly when Cre is expressed, and GFP to be consequently expressed from the T7 promoter in the presence of the T7 RNA polymerase. We were intending to use GFP expressed in this way as a positive control to our important assay, the “terminator leakiness assay.”

However, contrary to our expectation, Rossetta (DE3) pLysS possessing CRAD and a Cre recombinase generator under the control of the T7 promoter, BBa_K313008 on its plasmids did not express GFP even after addition of IPTG. As a control we have checked in advance that Rossetta (DE3) pLysS possessing the GFP generator under the T7 promoter expresses GFP when IPTG is added.

We hypothesized that the cause of this unexpected failure is that the lox sites used in the CRAD assay device were not functional. The grounds on which we construct this hypothesis are that the sequence of lox66, BBa_I718016, and this part lox71 registered as parts were different to lox66 and lox71 sequences reported in some scientific journals. (e.g. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC137435/) Our sequencing showed that all sequences of the CRAD were in agreement to those reported in papers except for those of the lox66 and lox71 sites.

So, our next move was to evaluate the functionality of the lox66 and lox71 sequences registered as parts. Of course, there also remained the possibility that Cre or the host E.coli strain was the problem. Therefore we designed an in vitro assay with the use of purified Cre protein in order to eliminate these possibilities. We added the purified Cre proteins to purified plasmids possessing CRAD, or to purified plasmids possessing lox sequences as reported in scientific journals. In the latter experiment, the sequence between two lox sites was excised, but in the former experiment, the sequence between lox66 and lox71 sites was not excised.

In conclusion, our hypothesis that lox66 and lox71 registered as parts are dysfunctional seems to be valid. As expected based on the discrepancy in the sequences, the CRAD possessing the lox sites from the registry did not express GFP in the presence of Cre. We therefore propose that these two lox sites should be replaced.

Retrieved from "https://parts.igem.org/Part:BBa_I718016:Experience"

iGEM12_USP_UNESP_Brazil

Based on the report made by the igem2010 UT-Tokyo team and some papers (e.g. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC137435/), the lox71 (BBa_I718017) from the registry was wrong, it had a cg instead a gc in the 8pb spacer sequence that is between the arms.

Apparently, this part was corrected by the iGEM11_WITS_CSIR_SA team (BBa_K537020), but the sequence from this group had the same error. The corrected part from iGEM11_Tokyo_Tech (BBa_K649205) was right but no DNA was available in the registry at the time of the competition.

We decided to synthesized the lox71 and test it, using the proper sequence described at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC137435/.

We submitted the correct DNA to the Registry (Part:BBa_K886000). We test it as part of the BBa_K886001 part that we developed. It worked.

More information:

http://2012.igem.org/Team:USP-UNESP-Brazil/Plasmid_Plug_n_Play/Introduction